Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress

被引：0
|
作者：
Newland, Adrian C.
Liebman, Howard A.
McDonald, Vickie
Michel, Marc
Miyakawa, Yoshitaka
Parys, Wim
De Haard, Hans
Ulrichts, Peter
Godar, Marie
De Beuf, Kristof
Ayguasanosa, Jaume
Broome, Catherine M.
Kuter, David J.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141161
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Efficacy and Safety of Fospropofol Disodium for Injection in General Anesthesia Induction for Adult Patients: A Phase 3 Trial
    Wu, Chao-Meng
    Zhang, Wen-Sheng
    Liu, Jin
    Zhang, Wei-Yi
    Ke, Bo-Wen
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [42] Efficacy and safety of Tildrakizumab in Australian patients with chronic plaque psoriasis in a phase 3 clinical trial
    Foley, P.
    Spelman, L.
    Fernandez-Penas, P.
    Freeman, M.
    Sinclair, R.
    Horton, J.
    Rozzo, S. J.
    Kurstjens, N.
    Shumack, S.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 56 - 56
  • [43] Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial
    Terui, Tadashi
    Kobayashi, Satomi
    Okubo, Yukari
    Murakami, Masamoto
    Zheng, Richuan
    Morishima, Hitomi
    Goto, Ryosuke
    Kimura, Takayuki
    [J]. JAMA DERMATOLOGY, 2019, 155 (10) : 1153 - 1161
  • [44] Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial
    Kumar, Princy N.
    Hernandez-Sanchez, Jules
    Nagel, Sandra
    Feng, Yuning
    Cai, Fang
    Rabin, Joseph
    Morse, Caryn G.
    Nadig, Nandita R.
    Ashraf, Obaid
    Gotur, Deepa B.
    McComsey, Grace A.
    Gafoor, Khalid
    Perin, Patrick
    Thornton, Sarah C.
    Stubbings, William
    Lin, Celia J. F.
    Tsai, Larry
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (01):
  • [45] Investigation of the efficacy and safety of eltrombopag to correct thrombocytopenia in moderate to severe dengue patients - a phase II randomized controlled clinical trial
    Chakraborty, Sajib
    Alam, Saruar
    Sayem, Mohammad
    Sanyal, Mousumi
    Das, Tonmoy
    Saha, Piyal
    Sayem, Mohammad D.
    Byapari, Bartholomia Keya
    Tabassum, Chowdhury Tamanna
    Kabird, Ahmedul
    Amin, Md Robed
    Nabi, A. H. M. Nurun
    [J]. ECLINICALMEDICINE, 2020, 29-30
  • [46] Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis
    Toshitaka Nakamura
    Tetsuo Nakano
    Masako Ito
    Hiroshi Hagino
    Junko Hashimoto
    Masato Tobinai
    Hideki Mizunuma
    [J]. Calcified Tissue International, 2013, 93 : 137 - 146
  • [47] Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis
    Nakamura, Toshitaka
    Nakano, Tetsuo
    Ito, Masako
    Hagino, Hiroshi
    Hashimoto, Junko
    Tobinai, Masato
    Mizunuma, Hideki
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2013, 93 (02) : 137 - 146
  • [48] Tolerability and safety of the intravenous immunoglobulin octagam® 10% in patients with immune thrombocytopenia: a post-authorisation safety analysis of two non-interventional phase IV trials
    Wietek, Stefan
    Svorc, Daniel
    Debes, Anette
    Svae, Tor-Einar
    [J]. HEMATOLOGY, 2018, 23 (04) : 242 - 247
  • [49] Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1 : Results from a Phase III Clinical Trial
    Saland, Jeffrey M.
    Lieske, John C.
    Groothoff, Jaap W.
    Frishberg, Yaacov
    Shasha-Lavsky, Hadas
    Magen, Daniella
    Moochhala, Shabbir H.
    Simkova, Eva
    Coenen, Martin
    Hayes, Wesley
    Hogan, Julien
    Sellier-Leclerc, Anne-Laure
    Willey, Richard
    Gansner, John M.
    Hulton, Sally -Anne
    [J]. KIDNEY INTERNATIONAL REPORTS, 2024, 9 (07): : 2037 - 2046
  • [50] Standard dosing (3mg/kg/day for 14 days) versus intermittent high dosing (10mg/kg day 1, 5mg/kg days 3 and 6) of liposomal amphotericin B for treating febrile neutropenia: A comparative prospective clinical trial of safety, efficacy and kinetics
    Ellis, M.
    Hedstrom, U.
    Ai-Ramadi, B.
    Alizadeh, H.
    Kristensen, J.
    Kshirsagar, S.
    Blaschke, T.
    Stevens, D. A.
    Klingspor, L.
    Poughias, L.
    [J]. PROCEEDINGS OF THE 8TH CONGRESS OF THE EUROPEAN ASSOCIATION FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2007, : 67 - +
12345